# CURRENT RESEARCH TOPICS IN PHARMACY:

## **Pharmacology Debates**

April 19th, 2023 10.00 AM ISTANBUL

FOR REGISTRATION:



First Session- Moderator: Esra TATAR 10.00-11.30 AM

Welcome- Prof. Hatice Kübra Elçioğlu Marmara University, İstanbul, Türkiye

The roles of cheminformatics in natural product-based drug discovery-Prof.Long Chiau Ming School of Medical and Life Sciences, Sunway University, Kuala Lumpur, Malaysia

Applications of machine learning to the lead discovery: Practical approaches – Dr.Said Moshawih Universiti Brunei Darussalam, Gadong, Brunei Darussalam

Second Session – Moderator: Ayşe Nur HAZAR YAVUZ 12:00-13.30 PM

Can Vitamin C supplements prevent premature rupture of membranes and preterm birth-Assist. Prof. Ana V. Pejcic University of Kragujevac, Kragujevac, Serbia

Drugs affecting newborn weight, length and head circumference at birth -Assist.Prof. Milos N. Milosavljevic University of Kragujevac, Kragujevac, Serbia

From traditional medicine to brain tumor theraphy using Plectranthus diterpenes-Assoc.Prof.Patricia Rijo

Chair Prof. Hatice Kübra ELÇİOĞLU

Vice Chairs Prof. Levent KABASAKAL & Assoc. Prof. Esra TATAF

ORGANIZING & SCIENTIFIC COMMITTEE Editorial Board of Journal of Research in Pharmac



Journal of Research in Pharmacy An international open-access journal of pharmacy and pharmaceutical sciences ONLINE SYMPOSIUM

Formerly published as Marmara Pharmaceutical Journal

# CURRENT RESEARCH TOPICS IN PHARMACY:

## Pharmacology Debates

April 19th, 2023 10.00 AM ISTANBUL

FOR REGISTRATION:



Third Session- Moderator: Mehmet GÜMÜŞTAŞ 14.00-15.30 PM

Side effects of COVID 19 vaccines and the contribution of graphenes- Assoc.Prof.Beril Anılanmert Institute of Forensic Sciences and Legal Medicine, Istanbul University-Cerrahpaşa, Istanbul, Türkiye

Knowledge and behaviour of medical university students about drug store and use-Assist.Prof.Klodiola Dhamo Aldent University. Tirana, Albania

The advancement of herbal-based treatments for hair loss- Dr.Oğuzhan Aydemir Istinye University, Istanbul, Türkiye

> **Chair** Prof. Hatice Kübra ELÇİOĞLU

Vice Chairs Prof. Levent KABASAKAL & Assoc. Prof. Esra TATAF

**ORGANIZING & SCIENTIFIC COMMITTEE** Editorial Board of Journal of Research in Pharmac



Journal of Research in Pharmacy

ONLINE SYMPOSIUM

An international open-access journal of pharmacy and pharmaceutical sciences Formerly published as Marmara Pharmaceutical Journal

### CURRENT RESEARCH TOPICS IN PHARMACY: Pharmacology Debates

#### April 19th, 2023 10.00 AM ISTANBUL

#### **ORGANIZING & SCIENTIFIC COMMITTEE**

Editorial Board of Journal of Research in Pharmacy <u>https://www.jrespharm.com/</u>

> Efe Doğukan Dincel Istanbul University, Istanbul, Türkiye

Ayşe Nur Hazar Yavuz (Secretary) mara University, Istanbul, Türkiy Abdikarim Mohammed Abdi Yeditepe University, Istanbul, Türkiye Afife Büşra Uğur Kaplan Atatürk Leiversity, Erzurum, Türkiye Ahmet Emir Ege University, Izmir, Türkive Ali Demir Sezer Marmara University, Istanbul, Türkiye Ammad Ahmad Farooqi omedical and Genetic Engineering (IBGE), Islamabad, Paki Ana V. Pejčić Anil Kumar Dwivedi Central Drug Research Institute, Lucknow, India Anisa Elhamili University of Tripoli, Tripoli, Libya Annalisa Chiavaroli G. d'Annunzio University of Chieti-Pescara, Chieti, Italy Antoaneta Trendafilova Bulgarian Academy of Sciences, Sofia, Bulgaria Ayça Toprak Semiz Giresun University, Giresun, Türkive Ayfer Beceren Marmara University. Istanbul. Türkiye Ayşe Esra Karadağ Istanbul Mediool University, İstanbul, Türkiye Ayşenur Günaydın Akyıldız Bezmialem Vakıf University, İstanbul, Türkiye Bahadır Bülbül Düzce University, Düzce, Türkiye Betul Okuyan Marmara University, Istanbul, Türkiye Beyza Ecem Öz Bedir Ankara Yıldırım Bayezit University Ankara Türkiye Burcu Üner arsity of Health Science and Pharmacy in St. Louis, USA Büşra Ertaş Marmara University. İstanbul. Türkiye Ceren Emir Foe Lloiversity Izmir Türkive Ceyda Ekentok Atıcı Marmara University İstanbul Türkiye Claudio Ferrante G. d'Annunzio University of Chieti-Pescara. Chieti. Italy Debora Dummer Meira Federal University of Espírito Santo, Vitória- Espírito Santo, Brazil Dhanashree P. Sanap Bharati Vidyapeeth's Collece of Pharmacy Navi Mumhai India Dinesh Kumar Indian Institute of Technology (BHU), Varanasi, India Ebru Altuntaş Istanbul University, İstanbul, Türkiye

Ela Hoti Liniversity of Medicine, Tirana, Albania Emine Terzi Ankara Yıldırım Bayezit University, Ankara, Türkiye Emirhan Nemutlu Hacettepe University, Anakara, Türkiye Emre Kara Hacettene University Anakara Türkiye Emrah Özakar Atatürk University, Erzurum, Türkiye Enkelejda Goci Aldent University, Tirana, Albania Entela Haloci University of Medicine, Tirana, Albania Erkan Rayaman Marmara University, Istanbul, Türkiye Fatiha Missoun Gizem Tatar Yılmaz Karadeniz Technical University Trahzon, Türkiye Gülberk Uçar Hacettepe University, Ankara, Türkiye Gülgün Tınaz Marmara University, İstanbul, Türkiye Gülşah Gedik Trakva University, Edirne, Türkive Haidar A. Abdulamir Al-Maad I Iniversity Basra Trad Hamide Sena Özbay Hacetteoe University. Ankara, Türkiye Hasan Erdinç Sellitepe Karadeniz Technical University, Trabzon, Türkiye İ. İrem Tatlı Çankaya Hacettene University Ankara Türkiye Kerem Buran University of Health Sciences, Istanbul, Türkiye Kleva Shpati Albanian University, Tirana, Albania Klodiola Dhamo Aldent I Iniversity Tirana Albania Laleh Khodaie iz University of Medical Sciences. Tabriz. Irar Lejla Klepo University of Saraievo. Saraievo. Bosnia and Herz Lokman Ayaz Trakya University, Edirne, Türkiye Lorena Memushaj Aldent University, Tirana, Albania Maja Ortner Hadžiabdić University of Zagreb, Zagreb, Croatia Mehmet Gümüştaş Ankara University. Ankara, Türkiye Merve Kabasakal University of Health Sciences, Istanbul, Türkiye Mesut Sancar Marmara University, Istanbul, Tijdvive Mirela Miraçi University of Medicine, Tirana, Albania Mirjana Marčetić University of Belgrade, Belgrade, Serbia

Murat Doğan Cumhuriyet University, Sivas, Türkiye Nasir Idkaidek Nurdan Tekin versity of Health Sciences, Istanbul, Türkiy Nurettin Yaylı iz Technical University. Trabzon. Türkiye Ongun Mehmet Saka Ankara University Ankara Türkive Oya Kerimoğlu Marmara University, İstanbul, Türkiye Pablo Miralles Ibarra University of Valencia, Buriassot, Soain Pankaj Dwivedi The University of Health Science and Pharmacy in St. Louis, USA Patrícia Rijo Lusofona University, Lisbon, Portugal Pınar Talay Pınar Yüzüncü Vil Universitu Van Türkiye Renuka Khatik Washington University in St. Louis, USA Rezarta Shkreli Aldent University, Tirana, Albania Rukiye Sevinç Özakar Atatürk University. Erzurum. Türkiye Rümeysa Keleş Kaya Sakarva University, Sakarva, Türkiye Saeideh Soltani Isfahan Liniversity of Medical Sciences, Isfahan, Irar Sakine Tuncay Tanrıverdi Ece University, İzmir, Türkiye Simone Carradori G. d'Annunzio" University of Chieti-Pescara, Chieti, Italy Sinan Sermet Istanbul Arel University. Istanbul. Türkiye Sneha Agrawal narati Vidvaneeth's College of Pharmacy, Navi Mumbai, Maharashtra, India Somaieh Soltani Tabriz University of Medical Sciences. Tabriz. Iran Tarik Catić Turgut Taşkın Marmara University. İstanbul. Türkiye Uğur Karagöz Trakva University, Edirne, Türkiye Ünzile Yaman Katip Çelebi University, İzmir, Türkiye Viktorija Maksimova ce Delcev University, Stip, Republic of N. Macedonia Vildan Çeliksoy Cardiff University Cardiff UK Vilma Toska Papajanı University of Medicine, Tirana, Albani Yeliz Şahin Ağrı İbrahim Çeçen University, Ağrı, Türkiye Zahraa Amer Hashim Mosul University Mosul Iraq Zarife Nigar Özdemir Kumral Marmara Linversity, İstanbul Türkiye Zeina Althanoon Mosul University, Mosul, Iraq Zoran Zeković University of Novi Sad, Novi Sad, Serbia

RP

### Journal of Research in Pharmacy An international open-access journal of pharmacy and pharmaceutical sciences

Mohd Younis Rather nent Medical College Srinagar, Srinagar, India

Formerly published as Marmara Pharmaceutical Journal

ONLINE SYMPOSIUM

### SIDE EFFECTS OF COVID VACCINES AND THE CONTRIBUTION OF GRAPHENE

#### Beril ANILANMERT<sup>®</sup>, Gülten RAYIMOGLU<sup>®</sup>, Fatma CAVUS YONAR<sup>®</sup>

Institute of Forensic Sciences and Legal Medicine, Istanbul University-Cerrahpasa, Istanbul, Türkiye.

beril.anilanmert@iuc.edu.tr

\*Presenting and corresponding author

The safety of COVID-19 vaccines became a concern for the masses, after the increasing number of reports of serious cardiac and neurological complications as blood clotting, Bell's palsy, myocarditis, cerebral venous thrombosis, etc., following the administration of specific vaccines. Till February 2022, more than 130 million COVID 19 vaccine doses had been distributed in France. During the first year of vaccination: 128,766 adverse events (AE) were reported. ~40,000 AE reported per year for all drugs in the pre-pandemic years [1].

The majority of a COVID-19 vaccines, work by expressing spike in the cells by infecting the cells with an adenovirus carrying a spike gene (AstraZeneca and Janssen vaccines) or by transfecting them with a spike mRNA (Pfizer and Moderna vaccines) and finally spike is recognized by the immune system as an antigen, triggering an immune response to SARS-CoV-2. However, there are some negative consequences with this mechanism: Spike mediated cell-cell fusion occurs resulting with syncytia [2].TMPRSS2, TMEM16F, phosphatidylserine and cholesterol are the endogenous elements enhancing syncytia. Syncytia are formed by S on infected cells, via interacting with ACE2 on other cells. Antibodies against spike protein S1 have been shown to have a high affinity toward other human tissue proteins, leading to autoimmune tissue damage in susceptible individuals [3]. Inducing IFN1 repeatedly with mRNA vaccines, can lead to depression and cognitive slowing. IFN-I stimulates cytokine storm. Exposure to spike protein can occur by natural infection or in higher amounts by repeated mRNA vaccination [4]. The amount and duration of spike protein exposure, age, cellular autophagy, and activation, function and regulation of p53 affects the formation of neurodegeneration.

The fusion of endothelial cells among themselves or with other cells e.g. platelets, can result in thrombosis, while the fusion of neurons may lead to neurological complications [2]. CD16+ monocytes can generate spike protein for months after vaccination. Presence of mRNA given in stabilized form in the body or reverse

transcribed mRNA to DNA might be responsible for this phenomena [5]. Spike has been optimized as a less fusogenic form in some vaccines when compared with Astra Zeneca [6]. The structure of the spike protein was slightly changed during manufacture through two mutations hindering a conformational change induced by binding to ACE2. This decreased cell fusion by several fold. So it is expected that the incidence of adverse effects would decrease. No manufacturer have yet mutated the S2' subunit, which includes the fusion peptide. Spike protein crosses the brainendothelial cell barrier.

Inactive vaccines as Sinovac would have an intermediate frequency of adverse effects since spike proteins in inactivated viruses can also cause cell fusion and syncytia according to the amount of injected inactive viruses. However, the reported side effects are less than mRNA vaccines. Different nucleotide compositions of RNA in different brands of vaccines have been reported to influence the immunization and reactogenicity of the vaccines at different levels. Additional complications may appear if the dose is not adjusted according to the geriatric and pediatric groups, and pregnants regarding the fetus.


Since the mutations in the gene coding S protein, which is the basic leg of the vaccines lead to new variants [7], serious concerns exist about the reduction in the vaccine efficacy. However, the advantage of VLP as in Turkovac (Turkey) is that the immune responses are produced through some parts of the spike protein (S) and matrix (M), envelope (E), and nucleocapsid (N) proteins. In the studies on Turkovac, no anaphylaxis or any serious side effects were reported except one myocarditis case with a 55 year old individual who was performing heavy sports [8].

Severe side effects as myocarditis, pericarditis, thrombosis, thromboembolism, thrombosis, thrombocytopenia, anaphylaxis, which cause hesitation in the uninfected healthy community have emerged with mostly AstraZeneca and mRNA vaccines as Moderna and Pfizer. Lymphadenopathy, bleeding, arthritis, heartburn, decrease in memory brain fogging/reduced mental clarity/attention, vertigo-like symptoms, paralysis, incoordination, palpitations, heat/cold intolerance are among the symptoms associated with BNT162b2 mRNA vaccine. Since the end of 2021 and throughout 2022, young age excess mortality has substantially increased in many European countries along with the progressing vaccination activities [9]. More deaths were reported in England in 2021 among 15-29 years old individuals, compared with the average of 5 years before the coronavirus pandemic (Table 1). Higher rates of myocarditis and pericarditis were determined in comparison to the rates in unvaccinated individuals [10].

Underlying cause of death	2021 Deaths	2021 % of total	2020 Deaths	2020 % of total	2019 Deaths	2019 % of total
All causes	2.125	56,5%	1.214	32,3%	321	8,5%
Diseases of the circulatory system	191	79,3%	44	18,3%	6	2,5%

Table 1. The ratios of death from the diseases of the circulatory system [11].

The excess mortality in the age group 0–14 started to increase significantly after the second half of 2021 and the graph in Figure 1. Figure 1 was constructed with data from 27 participating European countries [9,12].



**Figure 1.** Graph showing the excess mortality in the age group 0–14 until week 2022–51, generated with data from 27 participating European countries [9].

Also, interestingly, regarding the 26 cases of Creuzfeldt-Jacob Disease (diagnosed in 2021), first symptoms emerged in a mean of 11.38 days after vaccination with Pfizer, Moderna, or AstraZeneca. By 2023, only 1 remained alive [3].

Lower peak oxygen-consumption percentage, reduction in the peak-exercise heart rate, and lower ventilation values were noted in the vaccinated individuals. 8-12% of vaccinated individuals with breakthrough infections may develop long COVID [13]. Long COVID is suggested to appear as an initial outburst of antibody production leading to the formation of autoantibodies which attack the body and damage cells. Brain fog, headaches, oscillations in blood pressure were reported.

The association between the COVID-19 vaccine and the development of autoimmune syndromes should be further investigated especially regarding Graves disease, autoimmune liver diseases, immune thrombocytopenic purpurea, IgA nephropathy, autoimmune polyarthritis, systemic lupus erythematosus which were reported as the immunological side effects of vaccination [14].

Acute kidney injury was associated especially with Biontech, followed by Moderna and Janssen (ROR = 2.15, 95% confidence interval = 1.97, 2.36)

Pathologies have been demonstrated in animals: hepatitis and pulmonary eosinophilia,  $T_H$ 2-type immunopathology with eosinophils, pulmonary eosinophilia, eosinophil-associated  $T_H$ 2 immunopotentiation along with reinfection [16].

Due to the genetic diversity regarding populations, the complications of different vaccines among different populations should be investigated [17]. The prevalence of side effects was higher in overweight individuals (BMI>25) in the AZD-1222 and Covaxin vaccines.

Allergic reactions were reported by 12.7% of the Biontech vaccinees. The magnitude of COVID-19 vaccine adverse effects was comparatively higher in the existence of comorbid conditions. The current evidence suggests a lower frequency of side effects after Sinovac than the Pfizer and Astra-Zeneca vaccines.

The use of graphene has currently being searched for biomedical applications, as drug delivery, adjuvant for vaccines, etc. When chemically reduced, graphene oxide can create graphene which has been described as "the strongest, thinnest and most conductive material on the earth. It binds to peptides and antibodies, enzymes, metals and many molecules in the body including DNA. It is used in signal amplification for other purposes. Toxicities of graphene materials have been demonstrated on reproductive organs, lungs, liver, DNA (mutation), mitochondria, dermal fibroblast cells, T-lymphocytes, esophageal epithelium, renal epithelial cells, intestines (with the loss of microvilli), neurons, human erythrocytes, etc. They elevate ROS, induce immunotoxicity and cause pulmonary edema after injection. Graphene oxide is accumulated in different organs such as the lungs, liver, spleen, and bone marrow. Modified graphene oxide derivatives also used in DNA/RNA transfection, stabilizing RNA before transfection. Graphene derivatives pass through the fetus, studies on the blood-brain barrier.

A series of analyses using phase Contrast Microscopy, Dark Field and Bright Field Optical Microscopy, Transmission Electron Microscopy (TEM), and Energy-Dispersive X-ray spectroscopy (EDS) presented a list of evidence of toxic nanometallic particles, graphene oxide structures, and parasites (Tripanosoma kruzi) in COVID-19 vaccines [18-20]. The investigations with EDS, showed the presence of reduced graphene oxide or graphene hydroxide in the samples along with the other undisclosed ingredients. Luisetti used Transmission Electron Microscopy (TEM) Energy Dispersive Spectroscopy which gave the chemical nature of the observed micro and nano particulates and their morphology, an organic-inorganic aggregate was identified [19,20].

It is established with some literature studies that mRNA and can copy itself to host DNA via endogenous reverse transcryptase [21,22]. This may lead to changes in the DNA and transgenetic effects. It may not do it at the first shot in every individual. To increase the possibility, the vaccines carrying the genetic material RNA should be injected more than one.

DNA can be transferred from vaccinated to unvaccinated: Mother to infant while feeding; mother to fetus; between married partners. We don't know the severity and incidence of these advers events in the long term, and these types of vaccines should be evaluated more in terms of toxicity and the medical rule that «there is no disease there is patient». We suggest that the most important first step is the natural immunity that must be focused on and supported.

It is not certain or an estimated result that everyone will catch COVID 19 in the pandemic period, however it is certain that mass vaccination has been applied to individuals without knowing if they would catch COVID 19. In most of the literature studies, the vaccinated people were compared with the infected ones who were registered to a hospital. What about the people who were not infected because of working/living in isolated conditions with necessary precautions, or the ones who were mildly infected but not registered and healed on foot? Regardless of this foresight, we cannot comment as if all unvaccinated individuals will be infected with COVID 19 and has more risk of developing myocarditis than vaccinated. So new studies are needed with different universes as "vaccinated" and "unvaccinated" to be statistically evaluated. At that time the results will probably reverse.

**Keywords:** Vaccination for coronavirus infection; Side effects of COVID-19 vaccine; Adverse events; Graphene oxide toxicity; mRNA/vector/VLP based technologies

#### REFERENCES

- [1] Crommelynck S, Thill P. Pharmacovigilance for COVID-19 vaccines: A 1-year experience in France. Infect Dis Now. 2022; 52(8S): S16-S18. [CrossRef]
- [2] Li X, Yuan H, Li X, Wang H. Spike protein mediated membrane fusion during SARS-CoV-2 infection. J Med Virol. 2023;95(1):e28212. [CrossRef]
- [3] Perez JC, Moret-Chalmin C, Montagnier L. Emergence of a new Creutzfeldt-Jakob Disease: 26 cases of the human version of mad-cow disease, days after a COVID-19 Injection. Int J Vaccine Theory Pract Research. 2023; 3(1): 727-770. [CrossRef]
- [4] Kyriakopoulos AM, Nigh G, McCullough PA, Seneff S. Mitogen activated protein kinase (MAPK) activation, p53, and autophagy inhibition characterize the severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) spike protein induced neurotoxicity. Cureus. 2022;14(12):e32361. [CrossRef]
- [5] Seneff S, Kyriakopoulos AM, Nigh G, McCullough PA. A potential role of the spike protein in neurodegenerative diseases: A narrative review. Cureus. 2023;15(2):e34872. [CrossRef]
- [6] Lazebnik Y. Cell fusion as a link between the SARS-CoV-2 spike protein, COVID-19 complications, and vaccine side effects. Oncotarget. 2021; 12(25):2476-2488. [CrossRef]
- [7] World Health Organization (WHO). www.who.int (accessed June 22, 2021)
- [8] Kara A, Coskun A, Temel F, Özelci P, Topal S, Ates İ. Self-reported allergic adverse events following inactivated SARS-CoV-2 Vaccine (TURKOVAC<sup>™</sup>) among general and high-risk population. Vaccines (Basel). 2023;11(2): 437. [CrossRef]
- [9] EUROMOMO. https://euromomo.eu/dev-404-page/ (accessed December 24, 2022).
- [10] Karlstad Ø, Hovi P, Husby A, Härkänen T, Selmer RM, Pihlström N, Hansen JV, Nohynek H, Gunnes N, Sundström A, Wohlfahrt J, Nieminen TA, Grünewald M, Gulseth HL, Hviid A, Ljung R. SARS-CoV-2 vaccination and myocarditis in a Nordic cohort study of 23 million residents. JAMA Cardiol. 2022;7(6): 600-612. [CrossRef]
- [11] Nafilyan V, Bermingham C. COVID-19 vaccination and mortality in young people during the coronavirus pandemic, https://www.ons.gov.uk/peoplepopulationandcommunity/ healthandsocialcare/causesofdeath/datasets/deathsfollowingcovid19vaccinatio ninyoungpeopleduringthecoronavisuscovid19pandemicengland (accessed April 3,2023).
- [12] Monschein T, Hartung HP, Zrzavyl T, Barnett M, Boxberger N, Berger T, Chataway J, Bar-Or A, Rommer PS, Zettl UK. Vaccination and multiple sclerosis in the era of the COVID-19 pandemic. J Neurol Neurosurg Psychiatry. 2021;92:1033–1043. [CrossRef]

- [13] Al-Aly Z, Bowe B, Xie Y. Long COVID after breakthrough SARS-Co-V-2 infection. Nat Med. 2022;28:1461–1467. [CrossRef]
- [14] Chen Y, Xu Z, Wang P, Li XM, Shuai ZW, Ye DQ, Pan HF. New-onset autoimmune phenomena post-COVID-19 vaccination. Immunology. 2022;165(4):386-401. [CrossRef]
- [15] Luo H, Li X, Ren Q, Zhou Y, Chen G, Zhao B, Li X. Acute kidney injury after COVID-19 vaccines: a real-world study. Ren Fail. 2022;44(1):958-965. [CrossRef]
- [16] Lindsley AW, Schwartz JT, Rothenberg ME. Eosinophil responses during COVID-19 infections and coronavirus vaccination. J Allergy Clin Immunol. 2020;146:1-7. [CrossRef]
- [17] Zare H, Rezapour H, Mahmoodzadeh S, Fereidouni M. Prevalence of COVID-19 vaccines (Sputnik V, AZD-1222, and Covaxin) side effects among healthcare workers in Birjand city Iran. Int immunopharmacol. 2021;101: 108351. [CrossRef]
- [18] Young RO. Scanning and transmission electron microscopy reveals graphene oxide in CoV-19 vaccines. Acta Sci Med Sci. 2022;6(8):2582-0931.
- [19] Lee YM, Park S, Jeon KY. Foreign materials in blood samples of recipients of COVID-19 vaccines. Int J Vaccine Theory Pract Res. 2022;2(1): 249–265. [CrossRef]
- [20] Luisetto M, Almukthar N, Tarro G, Ahmadabadi NB, Edbey KEK, Khan FA, Hamid GA, Fiazza C, Cabianca L, Ilman I, Rafa YA, Rasool MG, Prince GG, Yurevich O. Graphene and derivates: Physico-chemical and toxicology properties in the mRNA vaccine manifacturing strategy. Sci World J Pharm Sci. 2022;1(2):1-23.
- [21] Zhang L, Richards AM, Barrasa MI, Hughes SH, Young RA, Jaenisch R. Reversetranscribed SARS-CoV-2 RNA can integrate into the genome of cultured human cells and can be expressed in patient-derived tissues. Proc Natl Acad Sci U S A. 2021;118(21):e2105968118. [CrossRef]
- [22] Chandramouly G, Zhao J, McDevitt S, Rusanov T, Hoang T, Borisonnik N, Treddinick T, Lopezcolorado FW, Kent T, Siddique LA, Mallon J, Huhn J, Shoda Z, Kashkina E, Brambati A, Stark JM, Chen XS, Pomerantz RT. Polθ reverse transcribes RNA and promotes RNA-templated DNA repair. Sci Adv. 2021; 7(24): eabf1771. [CrossRef]